Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1559733 | 0.87 | TAS1R3 (0.44) | TAS1R3TAS1R1TAS1R2ALDH1A1TSHR | |
| SCHEMBL444453 | 0.86 | KMT2A (0.44) | TAS1R3TAS1R1ALDH1A1TSHRBRD4 | |
| SCHEMBL21563864 | 0.74 | SLC6A2 (0.49) | TSHRBRD4 | |
| SCHEMBL1559785 | 0.69 | TTK (0.50) | PTK2TTK | |
| SCHEMBL30605709 | 0.68 | TTK (0.55) | PTK2TTK | |
| SCHEMBL410671 | 0.68 | AURKA (0.52) | PTK2BRD4 | |
| SCHEMBL23081287 | 0.67 | PARP1 (0.45) | ALDH1A1 | |
| SCHEMBL16956395 | 0.67 | PDE2A (0.33) | ALDH1A1 | |
| SCHEMBL2401169 | 0.66 | CARM1 (0.52) | — | |
| SCHEMBL16957168 | 0.63 | RXRA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303891-B1 | PYRAZOLO-QUINAZOLINES AS PROTEIN KINASE ACTIVITY MODULATORS | SERVIER LAB (FR) | 2016-02-17 | — | — | EP | disclosed |
| EP-2417125-B1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-09-09 | — | — | EP | disclosed |
| US-8846701-B2 | Pyrazolo-quinazolines | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-09-30 | — | — | US | disclosed |
| US-8772280-B2 | N-aryl-2-(2-arylaminopyrimidin-4-yl)pyrrol-4-carboxamide derivatives as MPS1 kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-08 | — | — | US | disclosed |
| US-20120065192-A1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-03-15 | — | — | US | disclosed |
| EP-2417125-A1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-02-15 | — | — | EP | disclosed |
| US-20110105542-A1 | PYRAZOLO--QUINAZOLINES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-05 | — | — | US | disclosed |
| EP-2303891-A1 | PYRAZOLO-QUINAZOLINES | Nerviano Medical Sciences S.r.l. (IT) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010108921-A1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-09-30 | — | — | WO | disclosed |
| WO-2009156315-A1 | PYRAZOLO-QUINAZOLINES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105542-A1 | PYRAZOLO--QUINAZOLINES | PDXK, MAP4K5, MAP3K1 | TAS1R3 3815/4885TAS1R1 2601/4885TAS1R2 3827/4885 |
| US-20120065192-A1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | PHKG1, PPM1A, PRKAG1 | TAS1R3 3941/4885TAS1R1 3374/4885TAS1R2 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.